BlackRock, Inc. 13D and 13G filings for Citius Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-05-08 2:22 pm Purchase | 2024-04-30 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 8,625,839 4.800% | 168,025 (+1.99%) | Filing |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 8,457,814 5.300% | 6,110,522 (+260.32%) | Filing |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 2,347,292 1.600% | -5,780,964 (-71.12%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | CITIUS PHARMACEUTICALS INC CTXR | BlackRock, Inc. BLK | 8,128,256 5.600% | 8,128,256 (New Position) | Filing |